Trials / Completed
CompletedNCT00649831
A Multicentre, Randomised, Open-Label Study To Compare The Efficacy And Safety Of Azithromycin For 5 Days With Those Of Amoxicillin-Clavulanic Acid In Patients With Chronic Bronchitis
Azithromycin (Zithromax®) 5 Days Versus Amoxicillin-Clavulanic Acid (Augmentin®): Multicentre, Randomised, Open-Label Study To Compare The Clinical Efficacy And Safety Of Azithromycin With Those Of Amoxicillin-Clavulanic Acid In Patients Presenting With An Exacerbation Of Chronic Bronchitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 250 (estimated)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 36 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
This study compared the clinical efficacy and safety of azithromycin with that of amoxicillin-clavulanic acid, in patients between the ages of 35 and 75 years, presenting with an exacerbation of chronic bronchitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Amoxicillin/clavulinic acid | amoxicillin/clavulinic acid 500 mg/62.5 mg tablet; take 2 tablets by mouth twice daily (BID) for 10 days |
| DRUG | Azithromycin | Azithromycin 250 mg tablet; take 2 tablets by mouth on the first day, then 1 tablet by mouth from Days 2 to 5 |
Timeline
- Start date
- 2002-10-01
- Completion
- 2003-06-01
- First posted
- 2008-04-01
- Last updated
- 2008-10-21
Locations
31 sites across 1 country: France
Source: ClinicalTrials.gov record NCT00649831. Inclusion in this directory is not an endorsement.